Aurobindo Receives FDA Approval for Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg
Published: February 13, 2024
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg. Aurobindo Pharma’s Atorvastatin Calcium Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), LIPITOR® Tablets manufactured by Upjohn Manufacturing Ireland Unlimited.
Atorvastatin Calcium Tablets are indicated for:
- Prevention of Cardiovascular Disease in Adults
- Hyperlipidemia.